In the Innovative Medicine Initiative (IMI2) report regarding rare diseases recently published. In the report, beside the several relevant recommendations on different topics such as digital solutions, innovative technologies, and a more explicit value framework for orphan drugs, a list of common challenges, and a note about public private partnership.
In addition, EJP RD as well as IRDiRC were mentioned under the European rare disease research leading consortia.
EJP RD is very honored and proud for being mentioned in this relevant report, which further strength our commitment on generating a virtuos circle around rare disease research.
